Glucagon-like peptide-1 receptor agonists show potential in reducing substance use disorders

1. Glucagon-like peptide-1 (GLP-1) receptor agonists are associated with a lower risk of developing new substance use disorders.

2. These medications may be influencing brain reward pathways, opening the door to new approaches in addiction research.

A large cohort study of more than 600,000 U.S. veterans is starting to shift how people think about glucagon-like peptide-1 (GLP-1) receptor agonists. These medications were linked to a lower risk of developing new substance use disorders when compared with sodium-glucose cotransporter-2 inhibitors. The reductions showed up across several substances, including opioids, nicotine, and cocaine. That kind of consistency is what makes these findings stand out. Researchers think this may come down to how these drugs interact with reward pathways in the brain. In other words, they may be dialing down the same systems that drive cravings. That idea lines up with what many patients have already been saying about feeling fewer urges beyond just food. The WashU Medicine report also noted fewer overdoses among people with pre existing substance use disorders. A BMJ study adds more detail and helps put the findings into a broader research context. That said, this is still observational data, so it cannot prove cause and effect just yet. Randomized trials will be needed to really understand what is going on. Researchers are also looking at how long these effects might last and whether they differ by substance. There is growing curiosity about whether these medications could eventually play a direct role in addiction treatment. For now, it is a surprising and potentially important signal from a class of drugs that keeps showing up in new places.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.